J&J Diabetes Drug Effective But Carries Risks, FDA Says

Law360, New York (January 8, 2013, 7:38 PM EST) -- The U.S. Food and Drug Administration raised concerns about safety risks in a new diabetes drug Johnson & Johnson is seeking approval for, directing an advisory committee this week to pay close attention to cardiovascular and bone risks, even as the agency said the drug is effective at lowering blood sugar.

An FDA advisory committee is meeting Thursday to consider whether to recommend that the agency approve the drug, canagliflozin, to treat type 2 diabetes. On Tuesday, the agency released its draft review of the drug...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.